search
Back to results

Gastric Volumes by US in Term Parturients Undergoing CS With and Without Metoclopramide

Primary Purpose

Pregnancy, Cesarean Section, Aspiration

Status
Recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Study drug metoclopramide
Study drug placebo administration
Sponsored by
Northwestern University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pregnancy focused on measuring Pregnancy, Gastric Volume, Ultrasound Measurement, Aspiration Prevention, Cesarean Section

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Healthy (ASA Physical Status 2)
  • Age >18 years old
  • Non-obese (BMI <40 kg/m2)
  • Age >18 years
  • Term (>37 week)
  • Non-laboring parturient
  • Single gestation
  • Scheduled for a cesarean delivery and NPO

Exclusion Criteria:

  • Systemic disease such as diabetes mellitus (type 1 or 2)
  • Multiple gestation
  • Abnormality of upper GI tract
  • History of GI tract related surgical procedures
  • Use of gastric motility medications
  • Active labor
  • Renal impairment (creatinine >2)
  • Non-English speaking
  • Cognitively impaired
  • History of QT prolongation
  • Use of general anesthesia

Sites / Locations

  • Northwestern Memorial Hospital and Prentice Women's HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Group 1 Study Drug Metoclopramide

Group 2 Study Drug Placebo

Arm Description

Intravenous administration of 10 mg metoclopramide

Intravenous administration of sterile normal saline

Outcomes

Primary Outcome Measures

Change in gastric volume (mL)
Change in gastric volume (mL) determined by ultrasound before and 30 minutes after administration of study drug

Secondary Outcome Measures

Incidence (number of events) of nausea and vomiting
Number of episodes (events) of intraoperative nausea and vomiting during cesarean delivery and post-operative nausea and vomiting after cesarean delivery (correlated to metoclopramide administration and gastric volume)
Adverse events
Number of adverse events (akathisia, dystonia, abdominal cramping, extrapyramidal symptoms) experienced between the two study groups.

Full Information

First Posted
August 27, 2021
Last Updated
January 16, 2023
Sponsor
Northwestern University
search

1. Study Identification

Unique Protocol Identification Number
NCT05033041
Brief Title
Gastric Volumes by US in Term Parturients Undergoing CS With and Without Metoclopramide
Official Title
Comparison of Gastric Volumes by Gastric Ultrasound in Term Parturients Undergoing Scheduled Elective Cesarean Delivery With and Without Metoclopramide
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 20, 2021 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
April 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Northwestern University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Our objective is to compare gastric volumes (mL) between women who receive metoclopramide versus placebo prior to scheduled cesarean delivery in appropriately fasted patients. If metoclopramide is found not to reduce gastric volumes this would inform future practice guidelines for obstetric anesthesia, which currently recommends metoclopramide administration prior to cesarean deliveries. We hypothesize that metoclopramide given to women with appropriate fasting prior to cesarean delivery does not result in any clinically significant reduction in gastric volume (mL) and therefore does not provide any additional benefit for aspiration prophylaxis but may expose patients to unnecessary side effects. A secondary objective will be to evaluate if gastric volume is a significant predictor of intraoperative nausea and vomiting.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pregnancy, Cesarean Section, Aspiration
Keywords
Pregnancy, Gastric Volume, Ultrasound Measurement, Aspiration Prevention, Cesarean Section

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Randomized controlled blinded study
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Research pharmacy to prepare the study medication blinding the participant, care providers, investigator and outcomes assessor.
Allocation
Randomized
Enrollment
72 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group 1 Study Drug Metoclopramide
Arm Type
Active Comparator
Arm Description
Intravenous administration of 10 mg metoclopramide
Arm Title
Group 2 Study Drug Placebo
Arm Type
Placebo Comparator
Arm Description
Intravenous administration of sterile normal saline
Intervention Type
Drug
Intervention Name(s)
Study drug metoclopramide
Intervention Description
Intravenous administration of 4 mg metoclopramide
Intervention Type
Drug
Intervention Name(s)
Study drug placebo administration
Intervention Description
Intravenous administration of placebo (sterile normal saline)
Primary Outcome Measure Information:
Title
Change in gastric volume (mL)
Description
Change in gastric volume (mL) determined by ultrasound before and 30 minutes after administration of study drug
Time Frame
30 minutes after administration of study drug
Secondary Outcome Measure Information:
Title
Incidence (number of events) of nausea and vomiting
Description
Number of episodes (events) of intraoperative nausea and vomiting during cesarean delivery and post-operative nausea and vomiting after cesarean delivery (correlated to metoclopramide administration and gastric volume)
Time Frame
24 hours
Title
Adverse events
Description
Number of adverse events (akathisia, dystonia, abdominal cramping, extrapyramidal symptoms) experienced between the two study groups.
Time Frame
48 hours

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
Pregnant undergoing cesarean section.
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Healthy (ASA Physical Status 2) Age >18 years old Non-obese (BMI <40 kg/m2) Age >18 years Term (>37 week) Non-laboring parturient Single gestation Scheduled for a cesarean delivery and NPO Exclusion Criteria: Systemic disease such as diabetes mellitus (type 1 or 2) Multiple gestation Abnormality of upper GI tract History of GI tract related surgical procedures Use of gastric motility medications Active labor Renal impairment (creatinine >2) Non-English speaking Cognitively impaired History of QT prolongation Use of general anesthesia
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jennifer Banayan, MD
Phone
(312) 472-3585
Email
jennifer.banayan@northwestern.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jennifer Banayan, MD
Organizational Affiliation
Northwestern University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Northwestern Memorial Hospital and Prentice Women's Hospital
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jennifer Banayan, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
28045707
Citation
Practice Guidelines for Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration: Application to Healthy Patients Undergoing Elective Procedures: An Updated Report by the American Society of Anesthesiologists Task Force on Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration. Anesthesiology. 2017 Mar;126(3):376-393. doi: 10.1097/ALN.0000000000001452. No abstract available.
Results Reference
background
PubMed Identifier
20993766
Citation
MENDELSON CL. The aspiration of stomach contents into the lungs during obstetric anesthesia. Am J Obstet Gynecol. 1946 Aug;52:191-205. doi: 10.1016/s0002-9378(16)39829-5. No abstract available.
Results Reference
background
PubMed Identifier
26580836
Citation
Practice Guidelines for Obstetric Anesthesia: An Updated Report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia and the Society for Obstetric Anesthesia and Perinatology. Anesthesiology. 2016 Feb;124(2):270-300. doi: 10.1097/ALN.0000000000000935. No abstract available.
Results Reference
background
Citation
4. Knight M, Bunch K, Tuffnell D, Shakespeare J, Kotnis R, Kenyon S, Kurinczuk JJ (Eds.) on behalf of MBRRACE-UK. Saving Lives, Improving Mothers' Care - Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2016-18. Oxford: National Perinatal Epidemiology Unit, University of Oxford 2020.
Results Reference
background
PubMed Identifier
26422744
Citation
Leus M, van de Ven A. IMAGES IN CLINICAL MEDICINE. An Acute Dystonic Reaction after Treatment with Metoclopramide. N Engl J Med. 2015 Oct;373(14):e16. doi: 10.1056/NEJMicm1412207. No abstract available.
Results Reference
background
PubMed Identifier
22307240
Citation
Mishriky BM, Habib AS. Metoclopramide for nausea and vomiting prophylaxis during and after Caesarean delivery: a systematic review and meta-analysis. Br J Anaesth. 2012 Mar;108(3):374-83. doi: 10.1093/bja/aer509. Epub 2012 Feb 3.
Results Reference
background
PubMed Identifier
20091567
Citation
Paranjothy S, Griffiths JD, Broughton HK, Gyte GM, Brown HC, Thomas J. Interventions at caesarean section for reducing the risk of aspiration pneumonitis. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD004943. doi: 10.1002/14651858.CD004943.pub3.
Results Reference
background
PubMed Identifier
23302981
Citation
Perlas A, Mitsakakis N, Liu L, Cino M, Haldipur N, Davis L, Cubillos J, Chan V. Validation of a mathematical model for ultrasound assessment of gastric volume by gastroscopic examination. Anesth Analg. 2013 Feb;116(2):357-63. doi: 10.1213/ANE.0b013e318274fc19. Epub 2013 Jan 9.
Results Reference
background
PubMed Identifier
24893784
Citation
Van de Putte P, Perlas A. Ultrasound assessment of gastric content and volume. Br J Anaesth. 2014 Jul;113(1):12-22. doi: 10.1093/bja/aeu151. Epub 2014 Jun 3.
Results Reference
background
PubMed Identifier
26097988
Citation
Arzola C, Perlas A, Siddiqui NT, Carvalho JCA. Bedside Gastric Ultrasonography in Term Pregnant Women Before Elective Cesarean Delivery: A Prospective Cohort Study. Anesth Analg. 2015 Sep;121(3):752-758. doi: 10.1213/ANE.0000000000000818.
Results Reference
background
PubMed Identifier
29265187
Citation
Arzola C, Perlas A, Siddiqui NT, Downey K, Ye XY, Carvalho JCA. Gastric ultrasound in the third trimester of pregnancy: a randomised controlled trial to develop a predictive model of volume assessment. Anaesthesia. 2018 Mar;73(3):295-303. doi: 10.1111/anae.14131. Epub 2017 Dec 19.
Results Reference
background

Learn more about this trial

Gastric Volumes by US in Term Parturients Undergoing CS With and Without Metoclopramide

We'll reach out to this number within 24 hrs